Lei Zhang1,2, Jeff Coombes3, Elaine M Pascoe1, Sunil V Badve1,4, Kim Dalziel5, Alan Cass1,6, Philip Clarke5, Paolo Ferrari1,7, Stephen P McDonald1,8, Alicia T Morrish1, Eugenie Pedagogos1,9, Vlado Perkovic1,10, Donna Reidlinger1, Anish Scaria1, Rowan Walker1,11, Liza A Vergara1, Carmel M Hawley1,4,12, David W Johnson1,4,12. 1. a Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia. 2. b Department of Nephrology , Guangdong Provincial Hospital of Chinese Medicine , Guangzhou , China. 3. c School of Human Movement Studies , University of Queensland , Brisbane , Australia. 4. d Department of Nephrology , Princess Alexandra Hospital , Brisbane , Australia. 5. e Center for Health Policy, Programs & Economics , University of Melbourne , Australia. 6. f Menzies School of Health Research , Darwin , Australia. 7. g Department of Renal Medicine , Fremantle Hospital , Australia. 8. h Department of Nephrology and Transplantation Services , University of Adelaide at Central Northern Adelaide Renal and Transplantation Services , Australia. 9. i Department of Nephrology , Royal Melbourne Hospital , Australia. 10. j George Institute , Sydney , Australia. 11. k Department of Renal Medicine , The Alfred Hospital , Melbourne , Australia. 12. l Translational Research Institute , Brisbane , Australia.
Abstract
OBJECTIVE:Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients. METHODS: This sub-study of the HERO trial compared 15 patients in thepentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities. RESULTS:Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD -6.06 U/l, P = 0.09), or protein carbonyls (MD -0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04). CONCLUSIONS:Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.
RCT Entities:
OBJECTIVE:Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKDpatients. METHODS: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities. RESULTS:Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD -6.06 U/l, P = 0.09), or protein carbonyls (MD -0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04). CONCLUSIONS:Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKDpatients with ESA-hyporesponsive anaemia.
Authors: R L Levine; D Garland; C N Oliver; A Amici; I Climent; A G Lenz; B W Ahn; S Shaltiel; E R Stadtman Journal: Methods Enzymol Date: 1990 Impact factor: 1.600
Authors: David W Johnson; Elaine M Pascoe; Sunil V Badve; Kim Dalziel; Alan Cass; Philip Clarke; Paolo Ferrari; Stephen P McDonald; Alicia T Morrish; Eugenie Pedagogos; Vlado Perkovic; Donna Reidlinger; Anish Scaria; Rowan Walker; Liza A Vergara; Carmel M Hawley Journal: Am J Kidney Dis Date: 2014-08-10 Impact factor: 8.860
Authors: Scott D Solomon; Hajime Uno; Eldrin F Lewis; Kai-Uwe Eckardt; Julie Lin; Emmanuel A Burdmann; Dick de Zeeuw; Peter Ivanovich; Andrew S Levey; Patrick Parfrey; Giuseppe Remuzzi; Ajay K Singh; Robert Toto; Fannie Huang; Jerome Rossert; John J V McMurray; Marc A Pfeffer Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245
Authors: Jonathan Himmelfarb; Stephen Phinney; T Alp Ikizler; Jane Kane; Ellen McMonagle; Guy Miller Journal: J Ren Nutr Date: 2007-09 Impact factor: 3.655
Authors: David Wayne Johnson; Carmel Mary Hawley; Brenda Rosser; Elaine Beller; Charles Thompson; Robert G Fassett; Paolo Ferrari; Stephen MacDonald; Eugenie Pedagogos; Alan Cass Journal: BMC Nephrol Date: 2008-08-01 Impact factor: 2.388
Authors: Ke Hu; Yi Guo; Yuxuan Li; Chanjun Lu; Chuanqi Cai; Shunchang Zhou; Zunxiang Ke; Yiqing Li; Weici Wang Journal: Front Cardiovasc Med Date: 2022-08-11